
Opinion|Videos|September 6, 2024
Biomarker Use in Patients on Active Surveillance
The panel explores the role of biomarkers in monitoring disease progression for prostate cancer patients on active surveillance, discussing how these tests aid in detecting changes that may warrant intervention.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- For patients on active surveillance, how do you use biomarkers?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves first-line Zenflow system for the treatment of BPH
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5























